이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis (ZENITH AD-2)

2026년 9월 4일 업데이트: Nektar Therapeutics

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to- Severe Atopic Dermatitis

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo.

The estimated participant overall duration is approximately 15 months.

연구 개요

연구 유형

중재적

등록 (추정된)

510

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Alabama
      • Birmingham, Alabama, 미국, 35203
        • 모병
        • Nektar Investigative Site
    • California
      • Oxnard, California, 미국, 93030
        • 모병
        • Nektar Investigative Site
      • Palmdale, California, 미국, 93551
        • 모병
        • Nektar Investigative Site
      • Sacramento, California, 미국, 95815
        • 모병
        • Nektar Investigative Site
    • Florida
      • Tamarac, Florida, 미국, 33321
        • 모병
        • Nektar Investigative Site
    • Georgia
      • Savannah, Georgia, 미국, 31406
        • 모병
        • Nektar Investigative Site
    • Louisiana
      • Metairie, Louisiana, 미국, 70006
        • 모병
        • Nektar Investigative Site
    • Missouri
      • Kirksville, Missouri, 미국, 63501
        • 모병
        • Nektar Investigative Site
      • Lee's Summit, Missouri, 미국, 64064
        • 모병
        • Nektar Investigative Site
    • Nevada
      • Las Vegas, Nevada, 미국, 89144
        • 모병
        • Nektar Investigative Site
    • New Jersey
      • Robbinsville, New Jersey, 미국, 08691
        • 모병
        • Nektar Investigative Site
    • New York
      • The Bronx, New York, 미국, 10455
        • 모병
        • Nektar Investigative Site
    • Ohio
      • Columbus, Ohio, 미국, 43213
        • 모병
        • Nektar Investigative Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • Male or female patients, ≥ 12 years of age on the day of signing the informed consent form and weighing ≥ 40 kg prior to randomization at Baseline
  • Chronic atopic dermatitis (AD) defined as onset of AD signs and symptoms

    ≥ 12 months prior to Screening as determined by the Investigator through patient interview and/or review of medical history at the Screening Visit

  • Patients must meet the following AD severity criteria:
  • IGA score ≥ 3 (scale of 0 to 4) at Screening and Baseline
  • ≥ 10.0% of BSA involvement at Screening and Baseline
  • EASI ≥ 16.0 at Screening and Baseline
  • Are candidates for systemic therapy and have history, documented by a physician and/or the Investigator, of inadequate response to existing topical medications within 6 months preceding Screening, or history of intolerance to a topical therapy
  • Provide written, informed consent to participate in the study and follow the study procedures, including compliance with the use of highly effective contraceptives

Exclusion Criteria:

  • Are currently experiencing or have a history of concomitant skin conditions other than AD, including skin infection in the area affected by the patient's AD that requires treatment with systemic antimicrobial therapy
  • Are currently experiencing or have a history of unstable course of AD
  • History of chronic idiopathic urticaria at any time or urticaria from other causes within 4 weeks prior to randomization at the Baseline Visit.
  • Have a history of TCS use suggestive of a high risk for topical corticosteroid (TCS) withdrawal
  • Have received any of the following treatments at any time before Screening: aldesleukin; investigational IL-2 analog; systemic biologic; oral JAKi; or any prior investigational agent for AD
  • Have a current or recent acute, active infection

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Blinded Induction Period: Rezpegaldesleukin every 2 weeks
Rezpegaldesleukin every 2 weeks during the induction period
약제 형태: 주사액 투여 경로: 피하
다른 이름들:
  • NKTR-358
위약 비교기: Blinded Induction Period: Placebo
Placebo every 2 weeks during the induction period
약제 형태: 주사액 투여 경로: 피하
실험적: Blinded Maintenance Period: Rezpegaldesleukin every 4 weeks
Rezpegaldesleukin every 4 weeks during the maintenance period
약제 형태: 주사액 투여 경로: 피하
다른 이름들:
  • NKTR-358
실험적: Blinded Maintenance Period: Rezpegaldesleukin every 12 weeks
Rezpegaldesleukin every 12 weeks during the maintenance period
약제 형태: 주사액 투여 경로: 피하
다른 이름들:
  • NKTR-358
위약 비교기: Blinded Maintenance Period: Placebo
Placebo every 4 weeks during the maintenance period
약제 형태: 주사액 투여 경로: 피하
실험적: Open-Label Escape
Rezpegaldesleukin at a frequency determined by the investigator during the open-label escape
약제 형태: 주사액 투여 경로: 피하
다른 이름들:
  • NKTR-358

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24
기간: Week 0 and Week 24
The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.
Week 0 and Week 24
Non-US regions only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 24
기간: Week 0 and Week 24
The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.
Week 0 and Week 24
Non-US regions only: Number of participants with a ≥ 75% reduction in Eczema Area and Severity Index (EASI) score from baseline at Week 24 (EASI-75)
기간: Week 0 and Week 24
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
Week 0 and Week 24

2차 결과 측정

결과 측정
측정값 설명
기간
US only: Number of participants with a ≥ 75% reduction in EASI score from baseline at Week 24 (EASI-75)
기간: Week 0 and Week 24
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
Week 0 and Week 24
Number of participants with a ≥ 90% reduction in EASI score from baseline at Week 24 (EASI-90)
기간: Week 0 and Week 24
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
Week 0 and Week 24
Number of participants at week 6 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline
기간: Week 0 and Week 6
The itch NRS goes from 0 to 10, with higher score indicating more severe itch.
Week 0 and Week 6
Number of participants at week 24 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline
기간: Week 0 and Week 24
The itch NRS goes from 0 to 10, with higher score indicating more severe itch.
Week 0 and Week 24
Number of participants at week 6 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline
기간: Week 0 and Week 6
The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.
Week 0 and Week 6
Number of participants at week 24 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline
기간: Week 0 and Week 24
The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.
Week 0 and Week 24
Number of participants at week 6 achieving a 1.25-point or greater improvement in Atopic Dermatitis Sleep Scale Question 1 (ADSS Q1) in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline
기간: Week 0 and Week 6
The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.
Week 0 and Week 6
Number of participants at week 24 achieving a 1.25-point or greater improvement in ADSS Q1 in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline
기간: Week 0 and Week 24
The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.
Week 0 and Week 24
Change in Asthma Control Questionnaire-5 (ACQ-5) score from baseline at Week 24 in the subpopulation of patients with a 0.5-point or greater ACQ-5 at baseline
기간: Week 0 and Week 24
The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.
Week 0 and Week 24
Number of participants at week 24 achieving a 0.5-point or greater improvement in ACQ-5 in the subset of participants with a 0.5-point or greater ACQ-5 at baseline
기간: Week 0 and Week 24
The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.
Week 0 and Week 24
Change in Sino-Nasal Outcome Test (SNOT-22) score from baseline at Week 24 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline
기간: Week 0 and Week 24
The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms
Week 0 and Week 24
Number of participants at Week 24 achieving a 8.9-point or greater reduction from baseline in SNOT-22 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline
기간: Week 0 and Week 24
The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms
Week 0 and Week 24
Number of participants at week 24 achieving an Adapted Investigator's Global Assessment (aIGA) response of 0 or 1
기간: Week 0 and Week 24
The aIGA scale ranges from 0 to 1, with a lower score indicating improvement in atopic dermatitis.
Week 0 and Week 24
Number of participants with treatment emergent adverse events (TEAEs)
기간: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with treatment emergent serious adverse events
기간: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with treatment related serious adverse events
기간: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with treatment emergent adverse events of special interest
기간: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with treatment related adverse events of special interest
기간: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with TEAEs leading to treatment discontinuation
기간: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with TEAEs leading to dose hold
기간: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with TEAEs leading to dose modifications
기간: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Study Director, Nektar Therapeutics

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 8월 7일

기본 완료 (추정된)

2028년 6월 1일

연구 완료 (추정된)

2029년 1월 1일

연구 등록 날짜

최초 제출

2026년 7월 14일

QC 기준을 충족하는 최초 제출

2026년 7월 14일

처음 게시됨 (실제)

2026년 7월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 8일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 4일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 25-358-10
  • 2025 (미국 NIH 보조금/계약: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
  • 2025-525129-11-00 (씨티스)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다